Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
Author:
Affiliation:
1. Environmental and Occupational Health Sciences, School of Public Health; Professor of Anesthesiology, School of Medicine, Louisiana State University Health Sciences Center, 2020 Gravier Street New Orleans, Louisiana 70112 USA
Publisher
Oxford University Press (OUP)
Subject
General Medicine
Link
http://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taaa041/32961230/taaa041.pdf
Reference6 articles.
1. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together;Verdecchia;Curr Vasc Pharmacol,2010
2. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?;Messerli;J Am Coll Cardiol,2018
3. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes;Winkelmayer;Am J Kidney Dis,2005
4. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2;Ferrario;Circulation,2005
5. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission;Xu;Life Sciences,2020
Cited by 275 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. COVID-19 Cases and Comorbidities: Complementary and Alternative Medicinal Systems (CAM) for Integrated Management of the Pandemic;Journal of Herbal Medicine;2023-12
2. What is naringenin?;Selçuk Üniversitesi Fen Fakültesi Fen Dergisi;2023-10-30
3. Pathological Interplay and Clinical Complications between COVID-19 and Cardiovascular Diseases: An Overview in 2023;Cardiology;2023-08-16
4. Naringenin: A flavanone with anti-inflammatory and anti-infective properties;Biomedicine & Pharmacotherapy;2023-08
5. COVID-19-Triggered Acute Liver Failure and Rhabdomyolysis: A Case Report and Review of the Literature;Viruses;2023-06-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3